These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34310191)

  • 1. At Preeclampsia Diagnosis, Total Cell-Free DNA Concentration is Elevated and Correlates With Disease Severity.
    Kolarova TR; Gammill HS; Nelson JL; Lockwood CM; Shree R
    J Am Heart Assoc; 2021 Aug; 10(15):e021477. PubMed ID: 34310191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation.
    Rafaeli-Yehudai T; Imterat M; Douvdevani A; Tirosh D; Benshalom-Tirosh N; Mastrolia SA; Beer-Weisel R; Klaitman V; Riff R; Greenbaum S; Alioshin A; Rodavsky Hanegbi G; Loverro G; Catalano MR; Erez O
    PLoS One; 2018; 13(7):e0200360. PubMed ID: 30001403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study.
    Tarca AL; Taran A; Romero R; Jung E; Paredes C; Bhatti G; Ghita C; Chaiworapongsa T; Than NG; Hsu CD
    Am J Obstet Gynecol; 2022 Jan; 226(1):126.e1-126.e22. PubMed ID: 34998477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Free Foetal DNA as a Useful Marker for Preeclampsia Prediction.
    Karapetian АО; Baev ОR; Sadekova АА; Krasnyi АМ; Sukhikh GT
    Reprod Sci; 2021 May; 28(5):1563-1569. PubMed ID: 33475978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome.
    Muñoz-Hernández R; Medrano-Campillo P; Miranda ML; Macher HC; Praena-Fernández JM; Vallejo-Vaz AJ; Dominguez-Simeon MJ; Moreno-Luna R; Stiefel P
    Am J Hypertens; 2017 Jul; 30(7):673-682. PubMed ID: 28338787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia.
    Rolnik DL; da Silva Costa F; Lee TJ; Schmid M; McLennan AC
    Ultrasound Obstet Gynecol; 2018 Dec; 52(6):722-727. PubMed ID: 29318732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Total Cell-Free DNA Levels Are Increased in Hypertensive Disorders of Pregnancy and Associated with Prohypertensive Factors and Adverse Clinical Outcomes.
    Amaral LM; Sandrim VC; Kutcher ME; Spradley FT; Cavalli RC; Tanus-Santos JE; Palei AC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness and reliability of cell free fetal DNA screening for main trisomies in case of atypical profile on first trimester maternal serum screening.
    Carrara J; Vivanti A; Jani JC; Demain A; Costa JM; Benachi A
    J Transl Med; 2019 Nov; 17(1):398. PubMed ID: 31779618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of fetal fraction with hypertensive disorders of pregnancy incidence and disease severity.
    Shree R; Kolarova TR; MacKinnon HJ; Lockwood CM; Chandrasekaran S
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100671. PubMed ID: 35644526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study.
    Barton JR; Woelkers DA; Newman RB; Combs CA; How HY; Boggess KA; Martin JN; Kupfer K; Sibai BM;
    Am J Obstet Gynecol; 2020 Mar; 222(3):259.e1-259.e11. PubMed ID: 31518550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
    O'Gorman N; Wright D; Syngelaki A; Akolekar R; Wright A; Poon LC; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jan; 214(1):103.e1-103.e12. PubMed ID: 26297382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction.
    Kwak DW; Kim SY; Kim HJ; Lim JH; Kim YH; Ryu HM
    Sci Rep; 2020 Jul; 10(1):11848. PubMed ID: 32678284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low fetal fraction in obese women at first trimester cell-free DNA based prenatal screening is not accompanied by differences in total cell-free DNA.
    Shree R; Kolarova TR; MacKinnon HJ; Hedge JM; Vinopal E; Ma KK; Lockwood CM; Chandrasekaran S
    Prenat Diagn; 2021 Sep; 41(10):1277-1286. PubMed ID: 34297415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes.
    Adekola H; Romero R; Chaemsaithong P; Korzeniewski SJ; Dong Z; Yeo L; Hassan SS; Chaiworapongsa T
    J Matern Fetal Neonatal Med; 2015; 28(14):1621-32. PubMed ID: 25211383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preeclamptic patient-derived circulating cell-free DNA activates the production of inflammatory cytokines via toll-like receptor 9 signalling in the human placenta.
    Ozeki A; Tani K; Takahashi H; Suzuki H; Nagayama S; Hirashima C; Iwata H; Kuwayama T; Ohkuchi A; Shirasuna K
    J Hypertens; 2019 Dec; 37(12):2452-2460. PubMed ID: 31385869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression analysis of MMPs in women with preeclampsia using cell-free fetal RNA in maternal plasma.
    Etesami E; Nikukar H; Ramezanali F; Ghotbizadeh Vahdani F; Shahhoseini M; Favaedi R; Ghaheri A; Seydabadi S; Zamanian M
    Pregnancy Hypertens; 2019 Jul; 17():261-268. PubMed ID: 31487650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of plasma cell-free DNA and ST2 as parameters in gestational hypertension and preeclampsia.
    Liu L; Li H; Wang N; Song X; Zhao K; Zhang C
    Hypertens Res; 2021 Aug; 44(8):996-1001. PubMed ID: 33864012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
    Poon LC; Musci T; Song K; Syngelaki A; Nicolaides KH
    Fetal Diagn Ther; 2013; 33(4):215-23. PubMed ID: 23466432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
    Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
    Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.